480 related articles for article (PubMed ID: 25887773)
1. Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis.
Oh J; O'Connor PW
Curr Opin Neurol; 2015 Jun; 28(3):230-6. PubMed ID: 25887773
[TBL] [Abstract][Full Text] [Related]
2. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
Oh J; O'Connor PW
Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
[TBL] [Abstract][Full Text] [Related]
3. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
[TBL] [Abstract][Full Text] [Related]
4. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
6. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.
Craddock J; Markovic-Plese S
Expert Rev Clin Pharmacol; 2015 May; 8(3):283-96. PubMed ID: 25916665
[TBL] [Abstract][Full Text] [Related]
8. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
10. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
11. Emerging injectable therapies for multiple sclerosis.
Oh J; Calabresi PA
Lancet Neurol; 2013 Nov; 12(11):1115-26. PubMed ID: 24090587
[TBL] [Abstract][Full Text] [Related]
12. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.
Biolato M; Bianco A; Lucchini M; Gasbarrini A; Mirabella M; Grieco A
CNS Drugs; 2021 Aug; 35(8):861-880. PubMed ID: 34319570
[TBL] [Abstract][Full Text] [Related]
13. Current and future trends in multiple sclerosis management: Near East perspective.
Hatem A; El Ayoubi NK; Habahbeh M; Ghanim Z; Al-Naqshbandi M; Raki A; Joudi H; Sahraian MA
Mult Scler Relat Disord; 2023 Aug; 76():104800. PubMed ID: 37307691
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
[TBL] [Abstract][Full Text] [Related]
15. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Fernández Ó
Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
[TBL] [Abstract][Full Text] [Related]
16. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
Pardo G; Jones DE
J Neurol; 2017 Dec; 264(12):2351-2374. PubMed ID: 28879412
[TBL] [Abstract][Full Text] [Related]
17. Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis.
Dubey D; Cano CA; Stüve O
Curr Opin Neurol; 2016 Jun; 29(3):272-7. PubMed ID: 27035896
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of relapsing-remitting multiple sclerosis.
Tanasescu R; Ionete C; Chou IJ; Constantinescu CS
Biomed J; 2014; 37(2):41-9. PubMed ID: 24732658
[TBL] [Abstract][Full Text] [Related]
19. Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.
Lucchetta RC; Tonin FS; Borba HHL; Leonart LP; Ferreira VL; Bonetti AF; Riveros BS; Becker J; Pontarolo R; Fernandez-Llimós F; Wiens A
CNS Drugs; 2018 Sep; 32(9):813-826. PubMed ID: 30014314
[TBL] [Abstract][Full Text] [Related]
20. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.
Lees S; Dicker M; Ku JE; Chaganti V; Mew-Sum M; Wang N; Smith A; Oldmeadow C; Goon WL; Bevan M; Lang D; Hinwood M
BMJ Open; 2021 Nov; 11(11):e051509. PubMed ID: 34728450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
